4x100ml Low Speed Angle Rotor 

Overview

• Ensure the stability and viability of viruses, chlamydia, and mycoplasma.
• Manufactured based on CDC formula.
• Antimicrobic blend suppresses bacterial and fungal contamination.
• Supplied in bulk (1 Litre) to provide options for custom applications.
• Preserve swab samples for up to 48h when preserved at 2–8°C.

Norgen’s Viral Transport Medium is formulated to transport samples that are presumably infected with a virus. Viral Transport Medium is manufactured based on CDC formula and is offered in bulk to provide an option to readily assemble swab collection devices for sample collection.

Norgen’s Viral Transport Medium (VTM) is designed for safe and efficient transport of viral samples, including but not limited to those from nasal, throat, and other swabs. The VTM contains a balanced mix of Hank’s Balanced Salt Solution (HBSS), heat-inactivated fetal bovine serum (FBS), gentamicin sulfate, and amphotericin B to preserve the viability of viruses and prevent the growth of contaminating bacteria and fungi. The medium ensures the stability and viability of viruses, chlamydia, and mycoplasma for analysis using different techniques. In addition, the Viral Transport Medium eliminates the need to immediately process or freeze samples.

Details

Storage Conditions and Product Stability
The Viral Transport Medium can be stored at 2-8°C for up to 1 year from the date of manufacturing without any reduction in performance.

Description

Specifications

Programmed Death-Ligand 1 (PD-L1), also known as CD274 or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumor cells resistant to CD8 T cell-mediated lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumor aggressiveness and risk of death, and, in ovarian cancer, higher expression of this protein has lead to significantly poorer prognosis. PD-L1 has also been linked to systemic lupus erythematosus and cutaneous melanoma. When considered in adjunct with CD8 tumor-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.